The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742
Sponsor: Celerion
Listed as NCT01797536, this PHASE1 trial focuses on Hepatic Insufficiency and remains completed. Sponsored by Celerion, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE1
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celerion
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .